Interferon-alpha, interferon-gamma and sizofiran in the adjuvant therapy in ovarian cancer--a preliminary trial.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Biotherapy

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 1290723
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Maintenance of the activation of peritoneal macrophages in patients with ovarian cancer by sizofiran and recombinant interferon-γ

  1992cited by this paper
• Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer.

  1990cited by this paper
• Prognostic factors for outcome of and survival after second‐look laparotomy in patients with advanced ovarian carcinoma

  1990cited by this paper
• Second‐look laparotomy in the patient with minimal residual stage III ovarian cancer (a Gynecologic Oncology Group study)

  1990cited by this paper
• [Sizofiran and recombinant interferon gamma stimulate peritoneal macrophages obtained from patients with gynecologic malignancies--increased secretion of tumor necrosis factor, IL-1 and interferon-gamma].

  1990cited by this paper
• Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma.

  1990cited by this paper
• [Effect of sizofiran or recombinant interferon gamma on the activation of human peritoneal macrophage function; an approach for the prophylaxis of intraperitoneal recurrence of ovarian cancer].

  1990cited by this paper
• Factor analysis of false-negative second-look laparotomy.

  1990cited by this paper
• Treatment of renal cell carcinoma with daily low-dose alpha-interferon.

  1989cited by this paper
• Cytokine-related immunomodulating activities of an anti-tumor glucan, sizofiran (SPG).

  1989cited by this paper
• Evaluation of treatment and survival after positive second‐look laparotomy

  1989cited by this paper
• Interferon in the treatment of ovarian cancer.

  1988cited by this paper
• Evaluation of the role of second‐look surgery in ovarian cancer

  1988cited by this paper
• Second‐look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with survival duration

  1988cited by this paper
• Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma.

  1988cited by this paper
• Similar biological effects of different low doses of interferon alpha in cancer patients.

  1987cited by this paper
• A review of second-look laparotomy for ovarian cancer.

  1986cited by this paper
• Second‐look laparotomy in managing epithelial ovarian carcinoma

  1986cited by this paper
• A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial.

  1985cited by this paper
• Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

  1985cited by this paper
• Prognosis of surgically determined complete responders in advanced ovarian cancer

  1985cited by this paper
• Second-look laparotomy in ovarian cancer: evaluation of pathologic variables.

  1985cited by this paper
• Recent immunologic advances affecting the management of ovarian cancer.

  1985cited by this paper
• The second-look surgical reassessment for epithelial ovarian carcinoma.

  1984cited by this paper
• Second-look laparotomy in stage III epithelial ovarian cancer: clinical variables associated with disease status.

  1984cited by this paper
• Effects of cloned human leukocyte interferons in the human tumor stem cell assay.

  1983cited by this paper
• Pharmacological and toxicological studies of a new antitumor polysaccharide, schizophyllan.

  1982cited by this paper
• Second-look operations in the planned management of advanced ovarian carcinoma.

  1982cited by this paper
• Second-look operations in ovarian cancer.

  1980cited by this paper
• Effects of surgery on the cell kinetics of residual tumor.

  1976cited by this paper
• Inhibition of the primary in vitro antibody response by interferon preparations.

  1975cited by this paper

• Beta-glucans is a potential inhibitor of ovarian cancer: based on molecular and biological aspects.

  2021cites this paper
• The Peritoneal Macrophages in Inflammatory Diseases and Abdominal Cancers.

  2018cites this paper
• Improving Outcomes through Immune System Modulation in the Treatment ofGynecological Malignancies

  2017cites this paper
• Immunotherapy for Ovarian Cancer

  2015cites this paper
• Interferon after surgery for women with advanced (Stage II-IV) epithelial ovarian cancer.

  2013cites this paper
• Inhibitory effect of ethyl acetate extract of the shaggy inc cap medicinal mushroom, Coprinus comatus (Higher Basidiomycetes) fruit bodies on cell growth of human ovarian cancer.

  2013cites this paper
• β-Glucans and their applications in cancer therapy: focus on human studies.

  2013cites this paper
• Tumor immune surveillance and ovarian cancer

  2011cites this paper
• Antitumor therapeutic effects of a genetically engineered Salmonella typhimurium harboring TNF-α in mice

  2011cites this paper
• Immune Therapy for Ovarian Cancer: Promise and Pitfalls

  2011cites this paper
• Cancer Immunotherapy and Nanomedicine

  2011cites this paper
• The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.

  2010cites this paper
• Tunicamycin Enhances the Anticellular Activity of Interferon by Inhibiting G1/S Phase Progression in 3T3 Cells

  2000cites this paper
• Gamma-interferon induces an irreversible growth arrest in mid-G1 in mammary epithelial cells which correlates with a block in hyperphosphorylation of retinoblastoma.

  1996cites this paper
• Enhanced expression of HLA-A,B,C and inducibility of TAP-1, TAP-2, and HLA-A,B,C by interferon-gamma in a multidrug-resistant small cell lung cancer line.

  1994cites this paper